[HTML][HTML] Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Y Wang, J Du, Z Gao, H Sun, M Mei, Y Wang… - British Journal of …, 2023 - nature.com
Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has
revolutionized the landscape of multiple human cancer types, including head and neck …
revolutionized the landscape of multiple human cancer types, including head and neck …
[HTML][HTML] TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
M Yi, T Li, M Niu, Y Wu, Z Zhao, K Wu - Frontiers in Immunology, 2022 - frontiersin.org
Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes,
such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides …
such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides …
[HTML][HTML] Immune checkpoint inhibitor resistance in soft tissue sarcoma
V Eulo, BA Van Tine - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
The emergence of immunotherapy as a cancer therapy has dramatically changed the
treatment paradigm of systemic cancer therapy. There have been several trials evaluating …
treatment paradigm of systemic cancer therapy. There have been several trials evaluating …
[HTML][HTML] Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
J Yang, Y Xu, Y Chen, T Li, X Zhang, T Hu… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
At the recent 2022 American Society of Clinical Oncology (ASCO) annual meeting, the latest
progress was presented in clinical trials of various therapeutic modalities for adult soft tissue …
progress was presented in clinical trials of various therapeutic modalities for adult soft tissue …
[HTML][HTML] The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: a multicenter retrospective study
Z Liu, X Wang, J Wang, P Zhang, C Li, B Wang… - Frontiers in …, 2023 - frontiersin.org
Objective: To investigate the efficacy and safety of antiangiogenesis-immunotherapy therapy
in patients with advanced STS in China, and to explore the potential factors of prognosis …
in patients with advanced STS in China, and to explore the potential factors of prognosis …
[HTML][HTML] m6A regulator-mediated methylation modification patterns and tumor immune microenvironment in sarcoma
Z Li, J Wei, H Zheng, X Gan, M Song, Y Zhang… - Aging (Albany …, 2022 - ncbi.nlm.nih.gov
Background: Studies have shown that the RNA N 6-methyladenosine (m 6 A) modification
patterns are extensively involved in the development of multiple tumors. However, the …
patterns are extensively involved in the development of multiple tumors. However, the …
[HTML][HTML] A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma
Z Li, H Zheng, L Liu, Z Fen, H Cao, J Yang… - Frontiers in …, 2022 - frontiersin.org
Background: Tumorigenesis and progression are intimately associated with inflammation.
However, the inflammatory landscape in soft tissue sarcoma (STS) and its clinical …
However, the inflammatory landscape in soft tissue sarcoma (STS) and its clinical …
